颈动脉内膜切除术后术中输注右旋糖酐无额外获益但与围术期主要不良心脏事件增加相关
基于血管质量倡议数据库2008至2022年140893例颈动脉内膜切除术患者,其中9935例(7.1%)术中输注右旋糖酐。多因素分析显示右旋糖酐与院内主要不良心脏事件风险升高相关,包括心肌梗死(OR 1.76)、充血性心力衰竭(OR 2.15)及需血管活性药物的血流动力学不稳定(OR 1.08),但未降低卒中(OR 0.92)或死亡(OR 0.88)风险。
要点
- 术中右旋糖酐与心肌梗死风险升高相关(OR 1.76,95%CI 1.34-2.3)。
- 术中右旋糖酐与充血性心力衰竭风险升高相关(OR 2.15,95%CI 1.67-2.77)。
- 右旋糖酐未降低卒中(OR 0.92)或死亡(OR 0.88)风险。
核心结论
- 术中输注右旋糖酐与主要不良心脏事件风险升高相关,包括心肌梗死、充血性心力衰竭和持续性血流动力学不稳定,且未降低围术期卒中风险。
研究设计与样本
- 基于血管质量倡议数据库的多机构回顾性研究,纳入2008年至2022年接受颈动脉内膜切除术的患者140893例,其中9935例(7.1%)术中输注右旋糖酐。
主要发现
- 术中右旋糖酐组年龄更大,症状性狭窄比例更低(24.7% vs. 29.3%;P < 0.001),术前抗血小板药、抗凝药和他汀类药物使用率更低。
- 术中右旋糖酐组严重颈动脉狭窄(>80%)比例更高(49% vs. 45%;P < 0.001),全身麻醉下手术比例更高(96.4% vs. 92.3%;P < 0.001),转流使用更频繁(64.4% vs. 49.5%;P < 0.001)。
- 校正后,术中右旋糖酐与院内主要不良心脏事件风险升高相关:心肌梗死OR 1.76(95%CI 1.34-2.3,P < 0.001)、充血性心力衰竭OR 2.15(95%CI 1.67-2.77,P = 0.001)、需血管活性药物的血流动力学不稳定OR 1.08(95%CI 1.03-1.13,P = 0.001)。
- 术中右旋糖酐与卒中风险降低无关(OR 0.92,95%CI 0.74-1.16,P = 0.489),与死亡风险降低无关(OR 0.88,95%CI 0.58-1.35,P = 0.554)。
- 按症状状态和狭窄程度分层后上述趋势持续存在。
临床怎么用
- 作者建议对接受颈动脉内膜切除术的患者审慎使用右旋糖酐。
- 作者认为对接受术中右旋糖酐的特定患者需进行仔细的围术期心脏管理。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intraoperative dextran infusion has been associated with reduction of an embolic risk in patients undergoing carotid endarterectomy (CEA). Nonetheless, dextran has been associated with adverse reactions, including anaphylaxis, hemorrhage, cardiac, and renal complications. Herein, we aimed to compare the perioperative outcomes of CEA stratified by the use of intraoperative dextran infusion using a large multiinstitutional dataset. METHODS: Patients undergoing CEA between 2008 and 2022 from the Vascular Quality Initiative database were reviewed. Patients were categorized by use of intraoperative dextran infusion, and demographics, procedural data, and in-hospital outcomes were compared. Logistic regression analysis was utilized to adjust for differences in patients while assessing the association between postoperative outcomes and intraoperative infusion of dextran. RESULTS: Of 140,893 patients undergoing CEA, 9,935 (7.1%) patients had intraoperative dextran infusion. Patients with intraoperative dextran infusion were older with lower rates of symptomatic stenosis (24.7% vs. 29.3%; P < 0.001) and preoperative use of antiplatelets, anticoagulants and statins. Additionally, they were more likely to have severe carotid stenosis (>80%; 49% vs. 45%; P < 0.001) and undergo CEA under general anesthesia (96.4% vs. 92.3%; P < 0.001), with a more frequent use of shunt (64.4% vs. 49.5%; P < 0.001). After adjustment, multivariable analysis showed that intraoperative dextran infusion was associated with higher odds of in-hospital major adverse cardiac events (MACE), including myocardial infarction [MI] (odds ratio [OR], 1.76, 95% confidence interval [CI]: 1.34-2.3, P < 0.001), congestive heart failure [CHF] (OR, 2.15, 95% CI: 1.67-2.77, P = 0.001), and hemodynamic instability requiring vasoactive agents (OR, 1.08, 95% CI: 1.03-1.13, P = 0.001). However, it was not associated with decreased odds of stroke (OR, 0.92, 95% CI: 0.74-1.16, P = 0.489) or death (OR, 0.88, 95% CI: 0.58-1.35, P = 0.554). These trends persisted even when stratified by symptomatic status and degree of stenosis. CONCLUSIONS: Intraoperative infusion of dextran was associated with increased odds of MACE, including MI, CHF, and persistent hemodynamic instability, without decreasing the risk of stroke perioperatively. Given these results, judicious use of dextran in patients undergoing CEA is recommended. Furthermore, careful perioperative cardiac management is warranted in select patients receiving intraoperative dextran during CEA.
引用
- Moore JM, Garg K, Laskowski IA, et al. Intraoperative Infusion of Dextran Confers No Additional Benefit after Carotid Endarterectomy but Is Associated with Increased Perioperative Major Adverse Cardiac Events. Ann Vasc Surg. 2023. PMID: 37004920. doi:10.1016/j.avsg.2023.03.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。